92 studies found for:    Open Studies | "Conjunctivitis"
Show Display Options
Rank Status Study
21 Recruiting Study for Evaluating Life Quality in Patients With Rhinoconjunctivitis
Condition: Allergic Rhinoconjunctivitis
Intervention:
22 Unknown  Allergic Eye Disease Tear Mediators
Condition: Allergic Eye Disease
Intervention: Drug: olopatadine
23 Recruiting Efficacy and Safety of LAIS® Mites Sublingual Tablets
Condition: Allergic Conditions
Intervention: Drug: LAIS®
24 Recruiting DBPC-trial of Subcutaneous Vitamin D3 Comparing Allergic Patients and Healthy Controls.
Condition: Hypersensitivity
Interventions: Drug: Paricalcitol;   Drug: Placebo (for paricalcitol)
25 Not yet recruiting Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Mite Allergy
Conditions: Rhinitis;   Rhinoconjunctivitis
Interventions: Biological: MM09 Mannosylated 5.000 subcutaneous;   Biological: MM09 Mannosylated 10.000 subcutaneous;   Biological: MM09 Mannosylated 30.000 subcutaneous;   Biological: MM09 Mannosylated 50.000 subcutaneous;   Biological: MM09 Mannosylated 5.000 sublingual;   Biological: MM09 Mannosylated 10.000 sublingual;   Biological: MM09 Mannosylated 30.000 sublingual;   Biological: MM09 Mannosylated 50.000 sublingual;   Biological: Subcutaneous placebo;   Biological: Sublingual placebo
26 Not yet recruiting Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen Allergy
Conditions: Rhinitis;   Rhinoconjunctivitis
Interventions: Biological: MG56 Mannosylated 5.000 subcutaneous;   Biological: MG56 Mannosylated 10.000 subcutaneous;   Biological: MG56 Mannosylated 30.000 subcutaneous;   Biological: MG56 Mannosylated 50.000 subcutaneous;   Biological: MG56 Mannosylated 5.000 sublingual;   Biological: MG56 Mannosylated 10.000 sublingual;   Biological: MG56 Mannosylated 30.000 sublingual;   Biological: MG56 Mannosylated 50.000 sublingual;   Biological: Subcutaneous placebo;   Biological: Sublingual placebo
27 Recruiting A Multicenter, Open Trial With Subcutaneous Immunotherapy (SCIT) in Patients With Rhinoconjunctivitis Sensitized to Parietaria Judaica
Condition: Rhinoconjunctivitis
Intervention: Biological: Allergovac depot with Parietaria judaica pollen extract
28 Recruiting Safety, Tolerability and Efficacy of the Depigmented Modified Allergen Extract of Two Mites in Subjects With Allergic Rhinitis or Rhinoconjunctivitis, With Controlled Allergic Asthma
Conditions: Rhinitis;   Rhinoconjunctivitis;   Asthma
Interventions: Biological: DP/MG/14-1;   Biological: DP/MG/14-2
29 Recruiting Sanitation, Water, and Instruction in Face-washing for Trachoma
Condition: Trachoma
Interventions: Behavioral: Water, sanitation, and hygiene (WASH) intervention;   Behavioral: Standard of care WASH intervention;   Drug: Azithromycin;   Drug: Tetracycline;   Other: Control
30 Not yet recruiting Performance of a Photoscreener for Vision Screening in a Haitian Pediatric Population
Conditions: Amblyopia;   Myopia;   Hyperopia;   Astigmatism;   Cataract;   Retinoblastoma;   Trachoma;   Xerophthalmia;   Glaucoma;   Retinopathy of Prematurity
Interventions: Device: Spot photoscreener;   Procedure: Ophthalmologic evaluation;   Procedure: Cyclopleged refraction
31 Recruiting Water Uptake for Health in Amhara Pilot
Condition: Trachoma
Intervention: Behavioral: instruction in soap-making and hygiene education
32 Recruiting Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Conditions: Infection;   Hypertension;   Pain;   Reflux;   Edema;   Hyperlipidemia;   Hypotension;   Hypercholesterolemia;   Sedation;   Anxiolysis;   Benzodiazepine Withdrawal;   Bipolar Disorder;   Autistic Disorder;   Schizophrenia;   Influenza Treatment or Prophylaxis;   Acute Decompensated Heart Failure;   Stable Angina;   Life-threatening Fungal Infections;   Nosocomial Pneumonia;   Community Acquired Pneumonia;   Acute Bacterial Exacerbation of Chronic Bronchitis;   Complicated Skin and Skin Structure Infections;   Uncomplicated Skin and Skin Structure Infections;   Chronic Bacterial Prostatitis;   Complicated Urinary Tract Infections;   Acute Pyelonephritis;   Uncomplicated Urinary Tract Infections;   Inhalational Anthrax (Post-Exposure);   Infantile Hemangioma;   Withdrawal;   Inflammation;   Bacterial Septicemia;   Cytomegalovirus Retinitis;   Herpes Simplex Virus;   Adenovirus;   Brain Swelling;   Airway Swelling;   Adrenal Insufficiency;   Anxiety;   Nausea;   Vomiting;   Convulsions;   Muscle Spasms;   Seizures;   Epilepsy;   Bartonellosis;   Brucellosis;   Cholera;   Plague;   Psittacosis;   Q Fever;   Relapsing Fever;   Rocky Mountain Spotted Fever;   Trachoma;   Tularemia;   Typhus Fever;   Bronchospasm;   Cardiac Arrest;   Hypersensitivity Reaction;   Cyanide Poisoning;   Acute Bacterial Sinusitis;   Bacterial Meningitis;   Sepsis;   Gastroparesis;   Opioid Addiction;   Migraines;   Headaches
Intervention: Drug: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
33 Not yet recruiting Evaluation of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease
Condition: Dry Eye Disease
Interventions: Drug: P-321 Ophthalmic Solution;   Drug: P-321 Ophthalmic Solution placebo
34 Not yet recruiting Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease
Condition: Tear Deficient Dry Eye Disease.
Interventions: Drug: P-321 Ophthalmic Solution;   Drug: P-321 Ophthalmic Solution placebo
35 Recruiting Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease
Conditions: Dry Eye Syndromes;   Keratoconjunctivitis Sicca
Interventions: Drug: KPI-121 0.25% Ophthalmic Suspension;   Drug: Vehicle of KPI-121 0.25% Ophthalmic Suspension
36 Not yet recruiting Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye
Condition: Dry Eye Syndromes
Interventions: Drug: AGN-195263;   Drug: Vehicle
37 Recruiting Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Conditions: Dry Eye Syndromes;   Keratoconjunctivitis Sicca
Interventions: Drug: KPI-121 0.25% Ophthalmic Suspension;   Drug: Vehicle of KPI-121 0.25% Ophthalmic Suspension
38 Recruiting Acute Tear Production Following Single Use of the Oculeve Intranasal Neurostimulator
Conditions: Dry Eye Syndrome;   Keratoconjunctivitis Sicca
Intervention: Device: Oculeve Intranasal Neurostimulator
39 Not yet recruiting Assessment of the Efficacy of Ocular Dipyridamole in the Treatment of Dry Eye Symptomology in Subjects With Pterygium
Conditions: Dry Eye Syndromes;   Pterygium
Interventions: Drug: Dipyridamole;   Drug: Placebo
40 Recruiting Study to Evaluate the Efficacy and Safety of CKD-350
Condition: Dry Eye Syndrome
Interventions: Drug: Xenobella;   Drug: Isotonic 0.3% Sodium Hyaluronate

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years